Midday trading saw sharp moves across sectors, led by cruise stocks after results, a surge in a cancer-focused biotech following upgraded guidance, and strength in AI- and energy-related names. Meanwhile, Fair Isaac tumbled on regulatory changes tied to mortgage pricing, and CarMax climbed after posting a quarterly beat.
Key takeaways
- Carnival jumped 12% after reporting third-quarter earnings and booking trends ahead of Wall Street expectations.
- Iovance Biotherapeutics rallied 26% on raised full-year revenue guidance.
- Oracle rose more than 5% after launching an agentic AI application aimed at deterministic enterprise workloads.
- Fair Isaac fell 18% after the Federal Housing Finance Agency signaled changes to mortgage pricing grids.
- CarMax gained over 5% following better-than-expected second-quarter results.
What drove the biggest gainers
Carnival outperformed after its quarterly update. The cruise operator reported third-quarter earnings ahead of Wall Street estimates before the market open, with management pointing to strong bookings despite ongoing consumer headwinds. Carnival also said the 2027 calendar year is booked at record occupancy, while 2028 occupancy and prices are higher year over year. Investors largely treated the update as evidence that demand is holding up through a softer consumer backdrop, lifting both sentiment and peers: Royal Caribbean rose about 6% and Norwegian Cruise Line advanced roughly 4% in sympathy.
Iovance Biotherapeutics surged after guidance moved higher. The cancer-focused biotech company raised its full-year revenue outlook to $410 million to $420 million, compared with $350 million to $370 million previously. The guidance upgrade was the primary driver of the stock’s 26% jump, reinforcing expectations for improved commercial trajectory.
Energy and AI-adjacent names also advanced. Bloom Energy shares jumped 13% after Jefferies raised its price target to $264 from $229 while maintaining a hold rating, citing a positive growth outlook. In a separate development, the city of Fremont, California, said on LinkedIn that Bloom Energy acquired a 158,000 square-foot facility for expansion—an item traders often interpret as incremental capacity and scaling momentum. In AI-linked activity, Lumentum gained 6%, Nebius Group rose 4%, and CoreWeave added nearly 2% as investors rotated into companies associated with the broader AI buildout.
Technology and enterprise AI focus
Oracle gained more than 5% following a new product launch. The database and enterprise software company debuted its Fusion Claw agentic application, which, according to a company statement, combines AI reasoning with deterministic enterprise computation to handle complex work “at scale.” The move suggests investors are leaning into the next phase of enterprise AI rollouts—particularly tools positioned to execute tasks within structured, governed environments rather than relying solely on probabilistic outputs.
SpaceX received a research catalyst. Shares rose about 2% after TD Cowen initiated research coverage with a buy rating. The analyst cited growth potential from both artificial intelligence and space exploration themes, providing a fresh valuation framework for the stock.
Why some stocks fell sharply
Fair Isaac dropped 18% after a housing-market policy change. The move came after Federal Housing Finance Agency director Bill Pulte introduced changes to mortgage pricing. In a post on X, Pulte said the agency is “Simplifying Mortgage Pricing” following feedback from lenders and consumers, moving away from two separate pricing grids to a single pricing grid, with VantageScore joining the existing FICO Classic pricing grid. Because Fair Isaac is a key provider of credit scoring and related analytics, investors appeared to reassess potential impacts on how mortgage pricing is structured and how credit models may be utilized.
Other notable company updates
Bloomin’ Brands added 3% after a JPMorgan rating change. The parent of Outback Steakhouse was upgraded by JPMorgan to neutral from underweight. The bank pointed to changes implemented by the restaurant chain, including a new steak lineup and a reduction in the table-to-server ratio during peak hours—from 6 tables to 4 tables—factors that can affect throughput and margin dynamics.
Summit Therapeutics rose 5% on a major funding and collaboration agreement. The drugmaker announced a $2 billion investment from AstraZeneca. In its release, Summit said it has agreements for a strategic equity investment and a clinical collaboration focused on ivonescimab and sonesitatug vedotin. Both drugs are being developed to treat cancer, and the transaction adds both capital and pipeline collaboration risk-sharing for shareholders.
CarMax climbed more than 5% after a quarterly beat. The used-car retailer reported second-quarter earnings of $1.16 per share on revenue of $7.88 billion. Analysts polled by FactSet expected profit of 73 cents per share on revenue of $7.09 billion, and the gap helped extend momentum for a stock that tends to trade closely with signals on retail demand and vehicle availability.
Bigger picture
The midday tape underscored how company-specific catalysts still dominated: investors rewarded raised guidance, earnings surprises, and new product or coverage-driven narratives, while policy-driven changes continued to hit credit and mortgage-adjacent names. With AI exposure trimming both winners and losers based on perceived execution paths, and consumer-linked sectors reacting to demand indicators, stock selection remained the central theme rather than broad market direction.
What to watch next: investors will likely monitor additional company results and forward guidance into the close, along with any further commentary tied to credit and mortgage frameworks. Upcoming data on consumer health and interest-rate expectations could also shape how investors interpret booking strength in travel and pricing sensitivity in financial services.
